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Key summary points
Aim The aim of this study was to determine whether DOAC-users with a hip fracture have delayed surgery, longer length 
of hospital stay or altered risk of bleeding complications compared to non-users.
Findings DOAC-users with a hip fracture did not have increased surgical delay, length of stay or risk of reported bleeding 
complications compared to patients without anticoagulation prior to surgery.
Message Our study does not support delayed surgery for DOAC-users suffering a hip fracture.
Abstract
Purpose The perioperative consequences of direct oral anticoagulants (DOACs) in hip fracture patients are not sufficiently 
investigated. The primary aim of this study was to determine whether DOAC-users have delayed surgery compared to non-
users. Secondarily, we studied whether length of hospital stay, mortality, reoperations and bleeding complications were 
influenced by the use of DOAC.
Methods The medical records of 314 patients operated for a hip fracture between 2016 and 2017 in a single trauma center 
were assessed. Patients aged < 60 and patients using other forms of anticoagulation than DOACs were excluded. Patients 
were followed from admission to 6 months postoperatively. Surgical delay was defined as time from admission to surgery. 
Secondary outcomes included length of hospital stay, transfusion rates, perioperative bleeding loss, postoperative wound 
ooze, mortality and risk of reoperation. The use of general versus neuraxial anaesthesia was registered. Continuous outcomes 
were analysed using Students t test, while categorical outcomes were expressed by Odds ratios.
Results 47 hip fracture patients (15%) were using DOACs. No difference in surgical delay (29 vs 26 h, p = 0.26) or length of 
hospital stay (6.6 vs 6.1 days, p = 0.34) were found between DOAC-users and non-users. DOAC-users operated with neuraxial 
anaesthesia had longer surgical delay compared to DOAC-users operated with general anaesthesia (35 h vs 22 h, p < 0.001). 
Perioperative blood loss, transfusion rate, risk of bleeding complications and mortality were similar between groups.
Conclusion Hip fracture patients using DOAC did not have increased surgical delay, length of stay or risk of reported bleed-
ing complications than patients without anticoagulation prior to surgery. The increased surgical delay found for DOAC-users 
operated with neuraxial anaesthesia should be interpreted with caution.
Keywords Hip fracture · Orthogeriatrics · Surgical delay · Anaesthesia · Direct oral anticoagulants (DOAC) · New oral 
anticoagulants (NOAC)
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Introduction
The use of direct oral anticoagulants (DOACs) have emerged 
based on randomized clinical trials, active marketing and 
less demands concerning monitoring compared to warfa-
rin. From 2014 to 2018, the prevalence of DOAC-users 
increased with 150% in Norway and the drugs as a group 
have surpassed warfarin [1]. Increasing use of DOACs has 
also been observed in Germany, Belgium and The Nether-
lands [2]. Suffering a hip fracture results in an evident excess 
mortality [3], and knowledge on how to reduce complica-
tions is, therefore, important. Reduced kidney function, co-
medication, drug interaction and altered distribution may 
affect the clinical outcome in hip fracture patients using such 
anticoagulant compounds [4].
Systemic thromboembolic events are important causes 
of mortality [5, 6]. On the other hand, DOACs may accen-
tuate bleeding triggered by trauma and surgery. Whether 
DOACs should be temporarily paused to avoid surgical and 
anaesthesiological complications and, if so, when it should 
be paused remains to be established. Anticoagulation has in 
several studies been identified as a risk factor for delayed 
hip fracture surgery [7–10]. Most guidelines advocate that 
hip fracture surgery should be performed within 48 h after 
admission, preferably within 24 h, to reduce the rate of 
medical complications and mortality [11–13]. Earlier stud-
ies have indicated that patients exposed for DOAC before 
the hip fracture wait longer for surgery than recommended in 
treatment guidelines [14–16]. The consequences of DOAC 
on semi-urgent surgery such as for hip fracture patients has 
not been thoroughly investigated.
Currently, there is need for guidelines on how to han-
dle DOACs in the treatment of hip fracture patients. The 
primary aim of this study was to determine whether hip 
fracture patients using DOACs prior to the fracture have 
delayed surgery or longer length of hospital stay compared 
to non-DOAC-users. Secondarily, we wanted to investigate 
whether mortality and perioperative complications occur 
more frequently among hip fracture patients using DOAC.
Methods
Study design
This is a retrospective descriptive study of hip fracture 
patients operated at one Norwegian single trauma center 
December 2016–December 2017. We extracted 360 patients 
electronically from the hospital database using ICD-10 diag-
nosis codes S72.0–S72.2. Demographic data and surgical 
outcomes for the included patients were retrieved directly 
from patient records by one experienced researcher (SLS). 
Patient records at the hospital consisted of day-to-day doc-
umentation by the anaesthetists and orthopaedic surgeons 
and medical records logged by physicians and nurses. The 
Regional Ethics Committee (REK) classified the study as 
quality assurance, thus we did not need ethical assessment 
(case number 1366/REK). The hospital data protection 
officer approved the study.
Patients
Patients with acute intracapsular or extracapsular hip frac-
tures undergoing any type of surgery were included in the 
study. We aimed to compare hip fracture patients using 
DOAC at time of fracture with patients without antico-
agulation at time of fracture. Patients under the age of 60 
(n = 23) and patients using other forms of anticoagulation 
than DOACs (n = 23) were excluded, resulting in a study 
population of 314 patients.
Outcomes
We stratified the patients according to the American Society 
of Anesthesiologists (ASA) classes 1–2 and 3–5 to compare 
comorbidity between the studied groups. When comparing 
the rate of cognitive impairment reported between the study 
groups, patients with unknown preoperative cognitive sta-
tus were excluded (n = 20). Time from admission to surgery 
(surgical delay) was reported in hours and length of stay 
(LOS) in days. In-hospital mortality and both mortality and 
readmissions within 30 days and within 6 months of opera-
tion were registered. Blood transfusion rates and transfusion 
amounts (allogenic red blood cells infused in standardized 
units) were collected from the medical records signed by the 
responsible physicians. In-hospital guidelines recommended 
blood transfusion therapy to be administered for patients 
with a haemoglobin below 9 g/dL monitored at the wards. 
The concentration of haemoglobin was listed at admission 
and the morning after surgery and the difference was calcu-
lated (change in haemoglobin concentration). Intraoperative 
blood loss estimated by the surgical team was registered 
from the anaesthesia journal in milliliters (mL). Postopera-
tive bleeding and wound complications were recorded if the 
intraoperative or postoperative journals by the physicians 
reported so. Wound ooze was defined as clinically identi-
fied ooze with or without bleeding described by the doctors 
postoperatively. The type of anaesthesia was registered as 
general anaesthesia (total intravenous anaesthesia (TIVA) 
or inhalational anaesthesia) or neuraxial anaesthesia (spinal 
anaesthesia). We compared surgical delay and LOS within 
the groups receiving neuraxial versus general anaesthesia.
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Statistical analysis
Our main outcome, surgical delay, was used to calculate 
the number of patients needed to achieve statistical signifi-
cance between the groups. Based on guidelines from the 
Norwegian Knowledge Center hip fracture patients should 
preferable be operated within 24 h and no later than 48 h 
after admission [12]. Standard deviation was calculated from 
hip fracture patients with a surgical delay of less than 96 h 
reported to the Norwegian Hip Fracture Register and found 
to be 15.1 h. Based on alpha of 0.05 and beta of 0.9, 28 
patients were needed in each group. Since 9.4% of Norwe-
gian patients > 60 years were using DOAC in 2017 (Norwe-
gian Institute of Public Health 2019), the total sample size 
was calculated to be 300. To account for exclusion criteria’s 
and missing information, we increased the sample size with 
20%.
We performed univariate exploration of study vari-
ables; for continuous data, the assumption of homogene-
ity of variance between groups was assessed using the 
Levene’s test. Where the assumption holds a Students t 
test was used, otherwise the Welch’s t test was applied. 
Odds ratios (ORs) were used to express categorical out-
comes and patients without DOAC were used as a ref-
erence group. IBM SPSS Statistics (version 24.0; IBM 
Corp. Armonk, New York) for Windows was used for the 
statistical analyses.
Results
Of the 314 included patients, 47 patients (15%) were DOAC-
users before the hip fracture and 267 patients (85%) were 
not using anticoagulation before the fracture (Table 1). Hip 
fracture patients using DOAC were more likely to have a 
high ASA class (ASA 3–5) compared to non-users.
Time to surgery and hospital stay
DOAC-users and non-anticoagulated patients had similar 
time interval from admission to surgery (29 vs 26 h, p = 0.26, 
respectively) and similar length of hospital stay (LOS) (6.6 
vs 6.1 days, p = 0.34, respectively) (Table 2).
Complications
The mean blood loss during surgery for all patients (n = 314) 
was 219 mL. Mean blood loss, fall in haemoglobin and 
transfusion rates were comparable in both groups (Table 2).
Bleeding complications were reported in three patients 
(0.9% of all patients); two patients had an excessive bleeding 
during surgery, while a third patient developed a postopera-
tive haematoma restricted to the operation site. No bleeding 
complications were reported among the DOAC-users.
Wound oozing with or without bleeding were described in 
27 patients (8.6%) and more frequently among DOAC-users 
than patients without anticoagulation (26% vs 5.6%, respec-
tively) (Table 2). Among all patients (n = 314), postoperative 
wound leakage was associated with a longer hospital stay 
than for patients without wound exudation (LOS 9 vs 6 days, 
respectively, p < 0.001).
The 30-day mortality for all patients (n = 314) was 12%. 
DOAC-users had corresponding mortality in the hospital, 
within 30 days and within 6 month compared to non-users 
(Table 2). Furthermore, 30-day and 6-month risk of read-
mission were similar between DOAC-users and non-users 
[30 days: 26% vs 17%, respectively, OR 1.65 (0.80–3.41)] 
[6 months: 36% vs 26%, OR 1.63 (0.85–3.13)].
Table 1  Baseline data for the 
included hip fracture patients in 
our study (n = 337)
a Pearson Chi Square test has been used to compare patients in each anticoagulant group with either ASA 
classes 1–2 or class 3–5. When comparing the rate of cognitive impairment reported between the study 
groups, patients with unknown preoperative cognitive status were excluded (n = 20)
Antithrombotic medication
Total No anticoagulants DOAC p value
Total n (%) 314 (100) 267 (85) 47 (15)
Mean age (SD) 82.1 (9.2) 81.8 (9.5) 84.2 (7.4) 0.05
Women (%) 221 (70) 190 (71) 31 (66) 0.47
Cognitive impairment (%) 108 (34) 93 (34.8) 15 (31.9) 0.61
ASA class (%) 0.003a
 ASA 1 8 (2.5) 8 (3.0) 0 (0.0)
 ASA 2 120 (39) 110 (42) 10 (21)
 ASA 3 158 (51) 128 (48) 30 (64)
 ASA 4 27 (8.0) 20 (7.5) 7 (15)
 ASA 5 1 (0.3) 1 (0.4) 0 (0.0)
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Antiaggregants
Among the DOAC-users, two hip fracture patients were also 
using clopidogrel (4.3%) while the remaining 45 patients 
where not using antiaggregant therapy (95.7%).
In the non-anticoagulated group, 92 patients (34.5%) were 
using 1 antiplatelet drug while ten patients (3.7%) were using 
two antiplatelet drugs. Time to surgery, perioperative blood 
loss, transfusion rate, risk of bleeding complications and 
mortality were similar between non-anticoagulated patients 
and DOAC-patients both when including and excluding 
patients with clopidogrel in addition to DOAC.
Anaesthesia
General anaesthesia was administered to 32 (10%) of all 
patients. When comparing general to neuraxial anaesthesia, 
no differences in time from admission to surgery (surgical 
delay) or LOS was found. A significantly higher percentage 
of DOAC-users received general anaesthesia than non-users 
[22 patients (47%) vs 10 (3.8%), p < 0.001]. The DOAC-users 
that received neuraxial anaesthesia (n = 25) had significantly 
longer surgical delay compared to those who received general 
anaesthesia (35 h vs 22 h, p < 0.001). DOAC-users treated 
with neuraxial anaesthesia trended toward a longer LOS, yet 
the results were not significant (7.1 vs 6.1 days, p = 0.1).
Discussion
In this single-centre retrospective descriptive study inves-
tigating hip fracture patients, the use of DOACs at the time 
of fracture was not found to influence surgical delay or 
length of stay compared to non-users. Furthermore, no dif-
ferences in perioperative blood loss, transfusion rates or 
risk of bleeding complications between DOAC-users and 
non-users were disclosed. Hip fracture surgery was more 
frequently performed in general anaesthesia in DOAC-
users, and the use of neuraxial anaesthesia for DOAC-users 
was associated with a longer surgical delay. This should 
be seen in relation to primary findings of no difference in 
surgical delay and length of stay between the compared 
groups. The high rate of cognitive impairment reported 
in this study was in line with a previous Norwegian study 
where 38% of home-dwelling hip fracture patients had cog-
nitive impairment [17].
Studies investigating hip fracture treatment and the use 
of anticoagulants have so far reported conflicting results. 
While increased risk of complications was detected in one 
study [18], other studies discovered no such effect [19, 20]. 
These diverse findings could be explained by different perio-
perative administration of anticoagulant drugs. Due to a lack 
of international established guidelines, patients tend to be 
treated according to local routines in each hospital.
Table 2  Surgical delay, length of hospital stay, type of anaesthesia, perioperative complications and mortality reported among hip fracture with 
DOAC or no anticoagulation prior to the fracture (n = 314)
Bold values indicate more frequent use of general anaesthesia and higher risk of wound ooze in DOAC-users compared to non-users
Antithrombotic medication
Hospital stay Total No anticoagulants DOAC p value
Hours from admission to surgery (SD) 26.5 (18.2) 26.1 (19.0) 28.9 (12.9) 0.26
LOS (SD) 6.2 (2.9) 6.1 (2.9) 6.6 (2.2) 0.34
General anaesthesia (%) 32 (10%) 10 (3.8%) 22 (47%) 0.001
Perioperative complications p value
Mean blood loss during surgery (SD) 219 mL (208) 218 mL (209) 223 mL (204) 0.9
Mean fall in haemoglobin (SD) 1.90 (1.30) 1.89 (1.25) 1.95 (1.63) 0.8
Mean SAG transfused per patient (SD) 0.81 (1.16) 0.80 (1.17) 0.85 (1.10) 0.8
OR (95% CI)
Number of patients transfused (%) 134 (43%) 113 (42%) 21 (45%) 1.10 (0.59–2.01)
Reported wound ooze (%) 27 (8.6%) 15 (5.6%) 12 (26%) 5.8 (2.49–13.3)
Mortality OR (95% CI)
In-hospital mortality 11 (3.5%) 9 (3.4%) 2 (4.3%) 1.27 (0.27–6.09)
30-day mortality 39 (12.4%) 34 (12.7%) 5 (10.6%) 1.23 (0.45–3.31)
6-month mortality 70 (22.3%) 59 (22.1%) 11 (23.4%) 0.93 (0.45–1.94)
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DOACs are approved for prevention of thromboembolism 
from non-valvular atrial fibrillation and to treat or prevent 
recurring deep vein thrombosis and pulmonary embolism 
[21–23]. These indications may explain why a higher burden 
of comorbidity was found among hip fracture patients using 
a DOAC compared to non-users in our study. Despite this 
increased comorbidity, we were not able to find increased 
risk of perioperative blood loss, transfusion rates, bleeding 
complications or mortality for the DOAC-users compared to 
the less comorbid non-users. Our findings are in contrast to 
another study reporting a higher one-year mortality among 
hip fracture patients using DOAC compared to non-users 
[24]. However, the excess mortality may be explained by 
higher age, more comorbidity and longer surgical delay than 
in our patients.
Earlier hip fracture surgery has been associated with 
reduced LOS and reduced frequency of immobilization-
related complications [25–28], and large resources have been 
applied to promote earlier surgical interventions [29]. Sev-
eral studies have found increased surgical delay for DOAC-
users [16, 18, 24], and the authors question whether the use 
of DOAC before the hip fracture results in unnecessary long 
surgical delay [14, 24, 30–32]. In contrast, our DOAC-using 
patients did not wait significantly longer for surgery than the 
non-users. Another study investigated hip fracture patients 
using DOACs compared to matched controls with a median 
of only 19 h from admission to surgery [30]; no association 
between surgical delay and perioperative fall in haemoglo-
bin, transfusion rate or reoperation for DOAC-users was 
found. As our study did not find increased bleeding—and 
transfusion—complications among patients using DOAC, 
early surgical interventions appear safe.
The prevalence and risk factors for surgical site infections 
is sparsely studied in the geriatric hip fracture population 
even though high age has been identified as a potential risk 
factor for such infections [33]. Our study revealed wound 
oozing five times more frequently among DOAC-users than 
patients without anticoagulation. Still, none of these patients 
underwent a reoperation due to wound ooze. We need to 
acknowledge that reoperation due to wound ooze is a late 
solution to persisting oozing. One earlier study has investi-
gated DOAC-users’ risk of reoperation due to wound ooze 
and found no relation to surgical delay [30]. On the other 
hand, when studying hip fracture patients not accounting for 
chronic anticoagulation, surgical delay has been found to be 
a risk factor for wound infections [28, 33]. The association 
between wound ooze and longer LOS found in our study 
might have implications for health costs and patient treat-
ment following a hip fracture.
In Norway, 80–90% of hip fracture patients are given 
neuraxial anaesthesia [34], correlating well to the preva-
lence found in our hospital (90%). There is no international 
consensus on neuraxial versus general anaesthesia for hip 
fracture patients [35]. General anaesthesia has earlier been 
associated with a longer LOS compared to neuraxial anaes-
thesia [36], yet a meta-study of 400,000 hip fracture patients 
revealed a clinically insignificant difference of only 0.3 days 
[37]. The increasing use of DOACs challenge current clini-
cal practice because the potential ramifications of neuraxial 
anaesthesia in the anticoagulated patient [38]. European 
guidelines recommend that DOACs should be discontinued 
before surgery in line with their pharmacokinetic proper-
ties [39–42]. Potential neuraxial bleeding can be avoided by 
giving the hip fracture patients general anaesthesia, possibly 
explaining why general anaesthesia was used ten times more 
frequently in patients using DOAC at the time of fracture 
compared to non-users in our study. One explanation to this 
finding could be that some DOAC-users were scheduled for 
delayed surgery to be operated with neuraxial anaesthesia. 
Another likely explanation is that for these DOAC-users, 
the chosen modality ended up being neuraxial anaesthesia, 
because their surgery already had been delayed for other 
reasons, in example access to theatre and preoperative medi-
cal stabilization.
Strengths and limitations
We studied patients treated at a large trauma hospital using 
patient records processed by one researcher, thereby increas-
ing the quality and reproducibility of our work. We cannot 
generalize our findings to other hospitals or countries with 
other treatment algorithms. However, we believe that our 
university hospital is representable also for hip fracture treat-
ment in other Norwegian hospitals. Similar surgical delay 
between DOAC-users and non-users further support com-
parable preoperative management of all the studied patients.
The sample size was calculated based on our main out-
come surgical delay using data from the Norwegian Hip 
Fracture Register [13]. However, we assessed several other 
outcomes as well in our study, thereby potentially working 
with insufficient sample sizes and lack of power. Unfortu-
nately, the size of our study prevented stratified analyses 
of the different types of DOAC. The retrospective study 
design allowed us to report associations between DOAC 
and perioperative outcomes, yet causality cannot be proven. 
For example, we cannot exclude the risk of confounding 
by comorbidity when it comes to the choice of anaesthesia 
and surgical delay. Due to the abovementioned weaknesses 
of our study, we request future prospective clinical trials 
targeting hip fracture patients exposed for DOACs and the 
consequences of fast track surgery versus surgery timed after 
drug excretion. Further, we acknowledge a need for further 
studies structurally targeting wound assessment and wound 
ooze for DOAC-users suffering a hip fracture.
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Conclusion
In our cohort of 314 hip fracture patients DOAC-users did 
not have increased surgical delay, LOS or risk of reported 
bleeding complications compared to patients without anti-
coagulation prior to surgery. Our study does not support 
delayed surgery for DOAC-users. The increased surgical 
delay found for DOAC-users operated with neuraxial anaes-
thesia compared to general anaesthesia should be interpreted 
with caution.
Acknowledgements Open Access funding provided by University of 
Bergen.
Author contributions SLS conducted the study of patient records. All 
authors participated in the study protocol, the application for ethical 
assessment and the manuscript.
Funding No funding was received.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethics approval The Regional Ethics Committee (REK) classified the 
study as quality assurance, thus we did not need ethical assessment 
(case number 1366/REK). The hospital data protection officer approved 
the study.
Consent to participate Our study involves hip fracture patients with 
a 1 year mortality of 25% and an even larger prevalence of cogni-
tive impairment. We have performed a descriptive study using patient 
records without consent due to the patient demographics (age, mortal-
ity and cognitive impairment) by conducting a risk assessment taking 
into account the potential gain in quality of future patient treatment. 
The Regional Ethics Committee (REK) classified the study as quality 
assurance, thus we did not need ethical assessment (case number 1366/
REK). The hospital data protection officer approved the study.
Consent for publication The hospital data protection officer approved 
the study. We refer to the classification from the Regional Ethics Com-
mittee.
Availability of data and material Our data have been deidentified and 
stored in a secure server area only available for Eva Dybvik and Sun-
niva Leer-Salvesen. The data will be deleted 5 years after the study.
Code availability IBM SPSS Statistics (version 24.0; IBM Corp. 
Armonk, New York) for Windows was used for the statistical analyses.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. No authors listed (2019) Norwegian Institute of Public Health, 
The prescription registry. Indivual site for retrieving data accessed 
05.12.19. https ://resep tregi stere t.no/Preva lens.aspx
 2. de Jong LA, Knoops M, Gout-Zwart JJ, Beinema MJ, Hemels 
MEW, Postma MJ, Boruwers JRBJ (2018) Trends in direct oral 
anticoagulant (DOAC) use: health benefits and patient preference. 
Neth J Med 76(10):426–430
 3. Solbakken SM, Meyer HE, Stigum H, Søgaard AJ, Holvik K, 
Magnus JH, Omsland TK (2017) Excess mortality following hip 
fracture: impact of self-perceived health, smoking, and body mass 
index. A NOREPOS study. Osteoporos Int 28(3):881–887
 4. Verma A, Ha ACT, Rutka JT, Verma S (2018) what surgeons 
should know about non-vitamin K oral anticoagulants: a review. 
JAMA Surg 153(6):577–585
 5. Vera-Llonch M, Hagivara M, Oster G (2006) Clinical and eco-
nomic consequences of bleeding following major orthopedic sur-
gery. Thromb Res 117(5):569–577
 6. Dahl OE, Caprini JA, Colwell CW Jr et al (2005) Fatal vascular 
outcomes following major orthopedic surgery. Thromb Haemost 
93(5):860–866
 7. Fantini MP, Fabbri G, Laus M et al (2011) Determinants of surgi-
cal delay for hip fracture. Surgeon 9(3):130–134
 8. Eardley WG, Macleod KE, Freeman H, Tate A (2014) “Tiers of 
delay”: warfarin, hip fractures, and target-driven care. Geriatr 
Orthop Surg Rehabil 5(3):103–108
 9. Tran T, Delluc A, de Wit C, Petrcich W, Le Gal G, Carrier 
M (2015) The impact of oral anticoagulation on time to sur-
gery in patients hospitalized with hip fracture. Thromb Res 
136(5):962–965
 10. Ranhoff AH, Martinsen MI, Holvik K, Solheim LF (2011) Use 
of warfarin is associated with delay in surgery for hip fracture in 
older patients. Hosp Pract 39(1):37–40
 11. No authors listed (2015) Norwegian Directorate of Health (Hel-
sedirektoratet). Preoperative wait time for hip fracture patients, 
National Quality Indicator System: Quality indicator description. 
https ://www.helse direk torat et.no/stati stikk /stati stikk /kvali tetsi 
ndika torer /behan dling -av-sykdo m-og-overl evels e/hofte brudd 
-opere rt-
 12. Lindahl AK, Talsnes O, Figved W et al (2014) Measures for 
increased survival after hip fractures. Publication from The 
National Knowledge Center for the Health Service. https://www.
fhi.no/globalassets/dokumenterfiler/notater/2014/tiltak-for-okt-
overlevelse-etter-hoftebrudd2 (date last accessed 16 July 2019)
 13. Leer-Salvesen S, Engesaeter LB, Dybvik E, Furnes O, Kristensen 
TB, Gjertsen JE (2019) Does time from fracture to surgery affect 
mortality and intraoperative medical complications for hip fracture 
patients? An observational study of 73 557 patients reported to the 
Norwegian Hip Fracture Register. Bone Jt J 101-B(9):1129–1137
 14. Hourston GJ, Barrett MP, Khan WS, Vindlacheruvu M, McDon-
nell SM (2019) New drug, new problem: do hip fracture patients 
taking NOACs experience delayed surgery, longer hospital stay, 
or poorer outcomes? Hip Int. https ://doi.org/10.1177/11207 00019 
84135 1
 15. Linnerud I, Viktil K, Ranhoff A, Molden E (2016) Bruk av direk-
tevirkende orale antikoagulantia og andre antitrombotika blant 
eldre hoftebruddspasienter; prevalens og kliniske aspekter. [The 
use of direct oral anticoagulants and other antithrombotic agents 
European Geriatric Medicine 
1 3
among elderly hip fracture patients; prevalence and clinical 
aspects] Master thesis in clinical farmacology at the University 
of Oslo in 2016. https ://www.duo.uio.no/bitst ream/handl e/10852 
/51405 /Ina-Linne rud-maste roppg -2016-DOAK-og-hofte brudd 
.pdf?seque nce=8. Accessed 05 Dec 2019
 16. Franklin NA, Ali AH, Hurley RK, Mir HR, Beltran MJ (2018) 
Outcomes of early surgical intervention in geriatric proximal 
femur fractures among patients receiving direct oral anticoagula-
tion. J Orthop Trauma 32(6):269–273
 17. Ranhoff AH, Holvik K, Martinsen MI, Domaas K, Solheim LF 
(2010) Older hip fracture patients: three groups with different 
needs. BMC Geriatr 10:65
 18. Frenkel Rutenberg T, Velkes S, Vitenberg M, Leader A, Halavy 
Y, Raanani P et al (2018) Morbidity and mortality after fragility 
hip fracture surgery in patients receiving vitamin K antagonists 
and direct oral anticoagulants. Thromb Res 166:106–112
 19. Gleason LJ, Mendelson DA, Kates SL, Friedman SM (2014) Anti-
coagulation management in individuals with hip fracture. J Am 
Geriatr Soc 62(1):159–164
 20. Cohn MR, Levack AE, Trivedi NN, Villa JC, Wellman DS, Lyden 
JP et al (2017) The hip fracture patient on warfarin: evaluating 
blood loss and time to surgery. J Orthop Trauma 31(8):407–413
 21. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, 
Parekh A et al (2009) Dabigatran versus warfarin in patients with 
atrial fibrillation. N Engl J Med 361(12):1139–1151
 22. Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib 
SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amer-
ena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, 
Granger CB, ARISTOTLE Committees and Investigators (2014) 
Amiodarone, anticoagulation, and clinical events in patients 
with atrial fibrillation: insights from the ARISTOTLE trial. J 
Am Coll Cardiol 64(15):1541–1550. https ://doi.org/10.1016/j.
jacc.2014.07.967
 23. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, 
Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, 
Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, 
ROCKET AF Investigators (2011) Rivaroxaban versus warfarin 
in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891
 24. Schermann H, Gurel R, Gold A, Maman E, Dolkart O, Steinberg 
EL et al (2019) Safety of urgent hip fracture surgery protocol 
under influence of direct oral anticoagulation medications. Injury 
50(2):398–402
 25. Grimes JP, Gregory PM, Noveck H, Butler MS, Carson JL (2002) 
The effects of time-to-surgery on mortality and morbidity in 
patients following hip fracture. Am J Med 112(9):702–709
 26. Verbeek DO, Ponsen KJ, Goslings JC, Heetveld MJ (2008) Effect 
of surgical delay on outcome in hip fracture patients: a retrospec-
tive multivariate analysis of 192 patients. Int Orthop 32(1):13–18
 27. Haleem S, Heinert G, Parker MJ (2008) Pressure sores and hip 
fractures. Injury 39(2):219–223
 28. Cordero J, Maldonado A, Iborra S (2016) Surgical delay as a risk 
factor for wound infection after a hip fracture. Injury 47(Suppl 
3):S56–S60
 29. Larsson G, Holgers KM (2011) Fast-track care for patients with 
suspected hip fracture. Injury 42(11):1257–1261
 30. Mullins B, Akehurst H, Slattery D, Chesser T (2018) Should 
surgery be delayed in patients taking direct oral anticoagulants 
who suffer a hip fracture? A retrospective, case-controlled 
observational study at a UK major trauma centre. BMJ Open 
8(4):e020625
 31. Lott A, Haglin J, Belayneh R, Konda SR, Leucht P, Egol KA 
(2019) Surgical delay is not warranted for patients with hip 
fractures receiving non-warfarin anticoagulants. Orthopedics 
42(3):e331–e335
 32. Hoerlyck C, Ong T, Gregersen M, Damsgaard EM, Borris L, Chia 
JK et al (2020) Do anticoagulants affect outcomes of hip fracture 
surgery? A cross-sectional analysis. Arch Orthop Trauma Surg 
140(2):171–176
 33. Liu X, Dong Z, Li J, Feng Y, Cao G, Song X et al (2019) Factors 
affecting the incidence of surgical site infection after geriatric hip 
fracture surgery: a retrospective multicenter study. J Orthop Surg 
Res 14(1):382
 34. Furnes O, Engesæter, LB, Gjertsen JE, Fenstad AM, Bartz-
Johannessen C, Dybvik E, Fjeldsgaard K, Gundersen T, Hallan 
G (2019) Annual report, Norwegian Arthroplasty Register 2019. 
https ://nrlwe b.ihels e.net/eng/Rappo rter/Repor t2019 _engli sh.pdf
 35. Johansen A, Golding D, Brent L, Close J, Gjertsen JE, Holt G, 
Hommel A, Pedersen AB, Rock ND, Thorngren KG (2017) Using 
national hip fracture registries and audit databases to develop an 
international perspective. Inj Int J Care Inj 48(10):2174–2179
 36. Neuman MD, Rosenbaum PR, Ludwiq JM, Zubizarreta JR, Silber 
JH (2014) Anesthesia technique, mortality, and length of stay after 
hip fracture surgery. JAMA 25(311):2508–2517
 37. Van Waesberghe J, Stevanovic A, Rossaint R, Coburn M (2017) 
General vs. neuraxial anaesthesia in hip fracture patients: a sys-
tematic review and meta-analysis. BMC Anesthesiol 17:8
 38. Jinlei L, Halaszynski T (2015) Neuraxial and peripheral nerve 
blocks in patients taking anticoagulant or thromboprophylactic 
drugs: challenges and solutions. Local Reg Anesth 8:21–32
 39. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp 
SL, Benzon HT et al (2010) Regional anesthesia in the patient 
receiving antithrombotic or thrombolytic therapy: American Soci-
ety of Regional Anesthesia and Pain Medicine Evidence-Based 
Guidelines (third edition). Reg Anesth Pain Med 35(1):64–101
 40. Gogarten W, Vandermuelen E, Van Aken H et al (2010) Regional 
anaesthesia and antithrombotic agents: recommendations of the 
European Society of Anaesthesiology. Eur J Anaesthesiol 27:999
 41. Wysokinski WE, McBane RD (2012) Periprocedural bridging 
management of anticoagulation. Circulation 126:486
 42. Narouze S, Benxon HT, Provenzano DA, Buvanendran A, De 
Andres J, Deer TR, Rauck R, Huntoon M (2015) Interventional 
spine and pain procedures in patients on antiplatelet and antico-
agulant medications: guidelines from the American Society of 
Regional Anesthesia and Pain Medicine, the European Society of 
Regional Anaesthesia and Pain Therapy, the American Academy 
of Pain Medicine, the International Neuromodulation Society, the 
North American Neuromodulation Society, and the World Insti-
tute of Pain. Reg Anesth Pain Med 40(3):182–212
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
